Project description
A game-changing solution for back pain
Intervertebral disc degeneration is a condition that affects the soft, cushion-like structures located between the bones that make up the spine. These discs serve as shock absorbers and allow for flexibility and movement in the spine. When they break down, they cause back pain, affecting millions of people worldwide. Funded by the European Innovation Council, the VitaDisc project aims to advance current symptomatic treatments and develop a groundbreaking, non-invasive solution that restores disc structure and supports regeneration. This acellular porcine-derived biomatrix is expected to address other unmet orthopaedic needs including early-stage knee joint arthritis.
Objective
Over 400 million people globally suffer from back pain. Disc degeneration disease is the prevalent cause of back pain and it is responsible for high social and economic costs. Current treatments are only symptomatic (physiotherapy, pain management or surgery), but they do not regenerate the disc and its function.
At NC Biomatrix, we have developed VitaDisc, the first non-invasive early restorative treatment for disc degeneration that has the power to revolutionise the orthopaedics market. It is an acellular porcine-derived injectable biomatrix that restores disc height, provides optimal support to regenerate the disc, and aids in restoring healthy spinal biomechanics. Its mode of action is fully mechanical, and it can be easily administered in an outpatient setting, giving it a unique market advantage.
Our biomatrix platform technology is readily scalable and provides a pipeline of further products for unmet needs in orthopaedic treatments, such as early-stage knee joint arthritis.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesclinical medicinerheumatology
- medical and health sciencesmedical biotechnologytissue engineering
- natural sciencesbiological sciencesbiophysics
- medical and health sciencesclinical medicineorthopaedics
- engineering and technologyindustrial biotechnologybiomaterials
You need to log in or register to use this function
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
5612AS EINDHOVEN
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.